The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...

Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Researchers have used AI to find adalimumab effective for iMCD, highlighting the potential of machine learning in discovering ...